Effectiveness of Hypertonic saline nasal irrigation and gargling in COVID-19
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/01/030236
- Lead Sponsor
- V M Hemlata Katiyar
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1. Adults (>=18 years)
2.Those presenting with any of the following:
a. Clinical symptoms suggestive of COVID-19 (i.e. those who have at least one of the following symptoms:
recent onset of
i) new continuous cough and/or
ii) high temperature) and/or
iii) loss of, or change in, sense of smell or taste (anosmia) and /or
b. Those with virologically confirmed SARS-CoV-2 infection and are admitted at the CFLTC or DH, Palakkad.
3. Provision of informed consent
1. People <=17 years
2. Inability to consent
3. Pregnancy
4. Immunosuppression
5. Inability to perform HSNIG
6. Those taking part in another interventional medical trial
7. Those without access to a supply of salt
8. Those who have had a negative COVID-19 swab result for the present symptoms
9. Those who opt for home isolation after testing Covid positive.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Self-reported time to resolution as assessed by completion of the validated self-reported, modified, short form of the Wisconsin Upper Respiratory Symptom Survey (WURSS-24), which will be used to collect daily symptom data.Timepoint: end of illness or 07 days
- Secondary Outcome Measures
Name Time Method 1. Severity of all symptoms <br/ ><br>2. The length of time for individual symptoms to resolve <br/ ><br>3. Severity of individual symptoms <br/ ><br>4. Any variations in the routine blood investigations done during the course of stay in hospital. <br/ ><br>5. Participants needing oxygen support/ developing hypoxia. <br/ ><br>6. Length of stay in hospital <br/ ><br>7. Number of participants reporting side effects of nasal irrigation <br/ ><br>8. Types and severity of side effects reported <br/ ><br>9. Extra cost incurred for the purpose of HSNIG <br/ ><br>Timepoint: end of illness or 07 days